Limited Stage I and II Follicular Non-Hodgkin's Lymphoma: The Nebraska Lymphoma Study Group Experience

References

• American Cancer Society: Cancer Facts and Figures. 1997
   Google Scholar
• Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2699–2707
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Simon R, Durrleman S, Hoppe RT, et al. The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Annals of Internal Medicine 1988; 109: 939–945
   PubMed Web of Science ®Google Scholar
• Paryani SB, Hoppe RT, Cox RS, et al. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983; 52: 2300–2307
   PubMed Web of Science ®Google Scholar
• Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. International Journal of Radiation Oncology, Biology, Physics 1984; 10: 489497
   Google Scholar
• Soubeyran P, Eghbali H, Bonichon F, et al. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. European Journal of Cancer 1991; 27: 1606–1613
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and Il indolent lymphomas at the National Cancer Institute. International Journal of. Radiation Oncology, Biology, Physics 1988; 14: 417–424
   PubMed Web of Science ®Google Scholar
• Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983; 52: 1–7
   PubMed Web of Science ®Google Scholar
• Monfardini S, Banfi A, Bonadonna G, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. International Journal of. Radiation Oncology, Biology, Physics 1980; 6: 125–134
   PubMed Web of Science ®Google Scholar
• Homing SJ. Low-grade lymphoma 1993: state of the art. Annals of Oncology 5 Suppl 1994; 2: 23–27
   Google Scholar
• Berinstein NL, Reis MD, Ngan BY, et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. Journal of Clinical Oncology 1993; 11: 1344–1352
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Fuller LM, Velasquez WS, et al. Stage 1–11 follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Anonymous. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Mann RB, Berard CW. Criteria for the cytologic sub-classification of follicular lymphomas: a proposed alternative method. Hematological Oncology 1983; 1: 187–192
   PubMedGoogle Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Anderson JR, Vose JM, Bierman PJ, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. Journal of Clinical Oncology 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Anderson T, Devita VT, Jr., Simon RM, et al. Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708–2721
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Parker D, Alison DL, Barnard DL, et al. Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematological Oncology 1994; 12: 15–27
   PubMed Web of Science ®Google Scholar
• Hayabuchi N, Jingu K, Masaki N, et al. Nodular histiocytic lymphoma, emphasizing results of stage I disease treated by radiotherapy. A report of the Japan Lymphoma Radiation Therapy Study Group (JLRTG). American Journal of Clinical Oncology 1990; 13: 501–506
   PubMed Web of Science ®Google Scholar
• Freedman A, Neuberg D, Gribben J, , Dicke K, Keating A, et al. Anti-B cell monoclonal antibody treated autologous bone marrow transplantation in patients with low grade non-Hodgkin's lymphomas. In the Proceedings of the Seventh International Symposia Autologous Marrow and Blood Transplantation (Arlington, Texas 1995). 1995; 321–331
   Google Scholar
• Gomez GA, Barcos M, Knshnamsetty RM, et al. Treatment of early-stages I and II-nodular. poorly differentiated lymphocytic lymphoma. American Journal of Clinical Oncology 1986; 9: 40–44
   PubMed Web of Science ®Google Scholar
• Taylor RE, Allan SG, McLntyre MA, et al. Low grade stage I and II non-Hodgkin's lymphoma: results of treatment and relapse pattern following therapy. Clinical Radiology 1988; 39: 287–290
   PubMed Web of Science ®Google Scholar
• Reddy S, Saxena VS, Pellettiere EV, et al. Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 687–692
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology 1996; 14: 1282–1290
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Eghbali H, Trojani M, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma?. Annals of Oncology 1996; 7: 713–718
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Lepomer M. Phase Il trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996; 14: 514–519
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czucz-Man MS, Wiiliams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Gribbin T, Estes J, Ross CW, et al. l-131 anti-B1 antibodyfor previously untreated follicular lymphoma: clinical and molecular remissions. Proc Am Sac Clin Onc 1998; 17: 6a
   Google Scholar